Tech Company Financing Transactions
iPierian Funding Round
On 9/8/2010, iPierian received $6 million in Series B funding from Biogen Idec and SR One Capital Management.
Transaction Overview
Company Name
Announced On
9/8/2010
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Investors
Proceeds Purpose
This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
951 Gateway Blvd
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nancy Stagliano
VP - Bus. Development
Adam Rosenthal
Browse more venture capital transactions:
Prev: 9/8/2010: TRACON Pharmaceuticals venture capital transaction
Next: 9/8/2010: Pasteuria BioScience venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs